Lasa Supergenerics Limited has filed a suit for Permanent injunction restraining infringement of its patent of Albendazole
MUMBAI, Mar 10 (The CONNECT) - Lasa Supergenerics Ltd, India’s Leading API (Active Pharmaceutical Ingredient) Manufacturer, has filed a suit in Bombay High Court for permanent injunction restraining infringement of its patent by Lohita Lifescience Pvt Ltd and others.
Lasa Supergenerics Limited has filed the suit covering “infringement of its patent, tortious interference, confidential breach and misuse of information, unfair trading etc. rendition of accounts and damages” to protect its product Albendazole.
Dr. Omkar Herlekar, Chairman & Managing Director, Lasa Supergenerics said, the company continues to keep close watch against offenders approach the relevant authorities to protect itself and the products.
The company has earlier obtained an ex-parte interim relief Bombay High Court against a competitor and a former employee of Lasa.
Albendazole belongs to a group of antiparasitic drugs called 'anthelmintic' used to treat parasites worm infections like neurocysticercosis (infection caused by pork tapeworm) and cystic hydatid disease (infection caused by dog tapeworm), according to information available on Apollo Pharmacy website.
Additionally, Albendazole is also used to treat infections caused by roundworms, hookworms, threadworm, whipworm, pinworm, flukes, and other parasites, the website says.
Incorporated in 2011, Lasa is a globally well-trusted API maker of high-quality products accepted by large pharma majors across the globe. The Company is a pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has state-of-the-art manufacturing facilities located at Mahad and Chiplun, Maharashtra, with a total installed capacity of 4,300 MT. The Company is steadily diversifying into hormonal APIs for human use. More than 25% of its APIs are exported to countries such as Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, and Pakistan.